FR104 / OSE Immunotherapeutics, Asahi Kasei 
Welcome,         Profile    Billing    Logout  
 5 Diseases   1 Trial   1 Trial   45 News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
FR104 / OSE Immunotherapeutics, Asahi Kasei
2020-000599-38: Phase 1/2 study of FR104 first administration In patient with Renal Transplantation: FIRsT study Étude de phase 1/2 : première administration de FR104 chez des patients ayant une première transplantation rénale : étude FIRsT

Not yet recruiting
1/2
10
Europe
FR104, FR104, Solution for infusion
NANTES CHU, OSE Immunotherapeutics
Kidney transplant Transplantés rénaux, Kidney transplant Transplantés rénaux, Diseases [C] - Symptoms and general pathology [C23]
 
 
FIRsT Study, NCT04837092: Phase I/II Study of FR104 First Administration In Patient With Renal Transplantation:

Active, not recruiting
1/2
10
Europe
FR104
Nantes University Hospital, OSE Immunotherapeutics
Kidney Transplantation
03/24
03/25
NCT05238493: A Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101

Completed
1
60
US
VEL-101, Placebo
Veloxis Pharmaceuticals
Healthy Volunteers
01/23
01/23

Download Options